The predominant cause of anemia in this patient population is a deficiency in erythropoietin. Continuous erythropoiesis receptor activator (CERA) is a new erythropoiesis-stimulating agent (ESA) that is undergoing ...
Anaemia in CKD 1-5MP190CONTINUOUS ERYTHROPOIETIN RECEPTOR ACTIVATOR (C.E.R.A.) DELAYS PROGRESSION OF KIDNEY DISEASE DUE TO EARLY SUPPRESSION OF GLOMERULOSCLEROSIS IN RATS WITH PROGRESSIVE GLOMERULONEPHRITISMP191CONTINUOUS ERYTHROPOIETIN RECEPTOR ACTIVATOR (C.E.R.A.) TREATMENT PREVENTS GLOMERULOSCLEROSIS ...
Although darbepoetin α is the first-choice supportive therapy for low-risk myelodysplastic syndrome, continuous erythropoietin receptor activator might be considered the second-choice therapy. 展开 关键词: Myelodysplastic syndromes Anemia Erythropoietin Renal dialysis ...
Monthly Administration of a Continuous Erythropoietin Receptor Activator Provides Efficient Haemoglobin Control in Non-Dialysis Patients during Routine Clinical Practice doi:10.2165/11594040-000000000-00000Clinical Drug InvestigationHeidenreich, StefanLeistikow, FrankZinn, StefanBaumann...
Erythropoietin deficiency is the major cause of anemia in hemodialysis patients. Although continuous erythropoietin receptor activator (CERA) has a long half-life and once-monthly administration is recommended, the optimal interval to achieve the greatest efficacy is not known. In 44 hemodialysis patients...
Furthermore, to the best of our knowledge, no study has investigated the use of epoetin β pegol (continuous erythropoietin receptor activator, CERA) as supportive therapy in patients with MDS. In this case report, we describe the use of CERA as supportive therapy in a patient with MDS who ...
Objective To evaluate the efficacy,safety and toler-ance of continuous erythropoietin receptor activator(CE-RA) once every 2 weeks intravenous injection on anemia correction in dialysis patients compared to Epoetin-β(EPO-β) administration. Methods An open label钱家麒China Medical Abstracts (Internal ...
Therapeutic Apheresis and DialysisDaimon S. Comparison of the effect of the same dose of a 4-weekly continuous erythropoietin receptor activator administered once every 2 or 4 weeks in hemodialysis patients. Ther Apher Dial. 2014;18:518-21....
In this study, iron-related parameters, including hepcidin levels, were explored in comparison to patients receiving continuous erythropoietin receptor activator ( CERA) and epoetin beta ( EPO) treatment. Ninety-four patients were randomized to receive monthly CERA ( N = 47) or EPO three times/...
HT-1080 Dynepo Erythropoietin Shire 2002(EU) (withdrawn 2009) HT-1080 Elaprase Idursulfase Shire 2006 (US) 2007 (EU) HT-1080 Vpriv INN-velaglucerase alpha Shire 2010 (US, EU) HEK 293 Alprolix rh factor IX fused to a human IgG1 Fc domain Biogen Idec 2014 (US) HEK 293 Eloctate rh ...